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Suppression of E-Cadherin Function Drives the
Early Stages of Ras-Induced Squamous Cell
Carcinoma through Upregulation of FAK and Src
Addy Alt-Holland1,2, Adam G. Sowalsky3, Yonit Szwec-Levin2, Yulia Shamis3, Harold Hatch3, Larry A. Feig4
and Jonathan A. Garlick1,5
Advanced stages of epithelial carcinogenesis involve the loss of intercellular adhesion, but it remains unclear
how proteins that regulate alterations in cell–cell and cell–matrix adhesion are deregulated to promote the early
stages of cancer development. To address this, a three-dimensional human tissue model that mimics the
incipient stages of squamous cell carcinoma (SCC) was used to study how E-cadherin suppression promotes
tumor progression in Ras-expressing human keratinocytes. We found that E-cadherin suppression triggered
elevated mRNA and protein expression levels of focal adhesion kinase (FAK), and increased FAK and Src
activities above the level seen in Ras-expressing E-cadherin-competent keratinocytes. The short hairpin RNA
(shRNA)-mediated depletion of FAK and Src restored E-cadherin expression levels by increasing its stability in
the membrane, and blocked tumor cell invasion in tissues. Surface transplantation of these tissues to mice
resulted in reversion of the tumor phenotype to low-grade tumor islands in contrast to control tissues that
manifested an aggressive, high-grade SCC. These findings suggest that the tumor-promoting effect of
E-cadherin suppression, a common event in SCC development, is exacerbated by enhanced E-cadherin
degradation induced by elevated FAK and Src activities. Furthermore, they imply that targeting FAK or Src in
human epithelial cells with neoplastic potential may inhibit the early stages of SCC.
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INTRODUCTION
Squamous cell carcinoma (SCC) is initiated as a foci of
cells with neoplastic potential that selectively undergo
intraepithelial expansion, degrade the basement membrane,
and invade into the stroma in the transition from precancer
to malignancy (Dlugosz et al., 2002). Although altered
tissue structure linked to loss of intercellular adhesion is a
morphologic hallmark of the intraepithelial stage of SCC
(Bissell and Radisky, 2001), the cellular events that promote
the conversion of a premalignant lesion to carcinoma, and
control its biological potential, are not well understood.
Signals directed by cadherin-mediated cell–cell adhesions
and integrin-mediated cell–matrix interactions regulate nor-
mal homeostasis of stratified squamous epithelia, whereas
perturbations of intercellular contacts can alter cell motility,
survival, and growth. E-cadherin that integrates cell-cell
adhesion in adherens junctions with mitogenic signaling is
known to play a critical role as a suppressor of invasiveness
(Cavallaro and Christofori, 2004; Yap et al., 2007). Loss
of E-cadherin function is most commonly associated with
advanced stages of SCC progression (Birchmeier and
Behrens, 1994; Behrens, 1999; Conacci-Sorrell et al.,
2002), and is linked to metastasis (Bissell and Radisky,
2001; Cavallaro and Christofori, 2004) and poor clinical
prognosis (Bagutti et al., 1998). Integrins that link matrix
components to the cytoskeleton in focal adhesions transmit
signals between the cells and the extracellular matrix to
regulate cell cycle, motility, and survival in normal and
tumorigenic cell contexts (Chen and Gumbiner, 2006).
However, it remains unclear how E-cadherin-mediated
cell–cell and integrin-mediated cell–matrix adhesions work
in concert to modulate and promote the early stages of SCC
development.
Focal adhesion kinase (FAK) and Src kinase are linked to
cadherins, growth factor receptors, and integrin-associated
signaling complexes (Playford and Schaller, 2004; Mitra and
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Schlaepfer, 2006; Zhao and Guan, 2009). FAK recruitment to
focal adhesions results in FAK autophosphorylation and,
consequently, activation of Src (Sieg et al., 2000; Roskoski,
2005). FAK hyperphosphorylation by Src directs focal
adhesion turnover and cell motility (Schlaepfer et al., 2004;
Mitra et al., 2005; Zhao and Guan, 2009). Src can also
increase cell motility by phosphorylating cadherin–catenin
complexes and regulators of adherens junctions, resulting in
E-cadherin internalization and cell spreading (Avizienyte
et al., 2002; Fujita et al., 2002; Frame, 2004). Upregulation of
FAK and Src has been correlated with the progression of a
variety of human cancers. Elevated FAK expression and
activity has been linked to breast (Oktay et al., 2003), colon
(Withers et al., 1996), prostate (Tremblay et al., 1996), and
oral (Schneider et al., 2002) cancers, whereas increased Src
activity has been shown in bladder carcinoma (Boyer et al.,
2002), head and neck (Mandal et al., 2008), colon (Aligayer
et al., 2002), and breast (Reissig et al., 2001) cancers.
Nevertheless, how FAK and Src regulate the early stages of
SCC remains unclear.
This study provides new insights into the functional
consequences of altered E-cadherin-mediated cell–cell adhe-
sion in the early stages of SCC development. In particular, we
found that tumor progression in a human three-dimensional
(3D) tissue model of SCC induced by oncogenic Ras and
E-cadherin suppression was associated with and required
the upregulation of FAK and Src activities that magnify
E-cadherin loss by increasing its turnover. Furthermore,
preventing the increase in FAK and Src activity associated
with loss of E-cadherin led to a marked decrease in
tumor growth and reverted tumor phenotype from high- to
low-grade carcinoma in vivo. These findings demonstrate a
critical mechanism by which E-cadherin loss drives the early
stages of SCC development through enhanced FAK and
Src kinase activities.
RESULTS
E-cadherin suppression in Ras-transformed keratinocytes is
associated with elevated FAK expression and FAK and Src
tyrosine phosphorylation that promote enhanced cell motility
To better understand how E-cadherin suppression and FAK
and Src activities are related during early stages of SCC
development, we studied FAK and Src function when Ras-
expressing HaCaT-II-4 keratinocytes (II-4 cells) are converted
to invasive cells (H-2Kd-Ecad-II-4 cells). This occurs by an
overexpression of a dominant-negative E-cadherin fusion
protein (H-2Kd-Ecad), which through cytoplasmic sequestra-
tion of b-catenin leads to destabilization of E-cadherin–
b-catenin complexes and the loss of cadherin-mediated
intercellular adhesion (Zhang et al., 2006). As elevated FAK
activity is linked to increased phosphorylation at its autopho-
sphorylation site (Tyr397), activation loop (Tyr576/577), and
FAT domain (Tyr925; Katz et al., 2003), we compared
FAK expression and phosphorylation in both cell lines.
Immunoblotting revealed that, compared with non-invasive
II-4 cells, invasive H-2Kd-Ecad-II-4 cells showed an approxi-
mately twofold increase in FAK expression and elevated FAK
phosphorylation at tyrosine Tyr397, Tyr576/577, and Tyr925
(Figure 1a). Furthermore, quantitative real-time reverse
transcriptase PCR showed that the increase in FAK expression
was associated with a significant upregulation of FAK mRNA
level (Figure 1b). Next, we explored whether the increase
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Figure 1. Loss of E-cadherin function is associated with upregulation of focal adhesion kinase (FAK) and Src expression and/or phosphorylation. (a) Western
blot (WB) analysis of lysates of H-2Kd-Ecad-II-4 cells revealed an increase in the expression and specific tyrosine phosphorylation of FAK. (b) Quantitative real-
time reverse transcriptase-PCR (qRT-PCR) analysis revealed a significant increase in FAK mRNA expression in H-2Kd-Ecad-II-4, relative to its level in II-4 cells.
The mean±SD values of FAK or Src mRNA expression levels in H-2Kd-Ecad-II-4 relative to II-4 cells are shown. (c) WB analysis showed similar expression levels
of Src protein in both cell lines. (d) WB and ratio analysis of cell fractions of the two cell lines revealed increased tyrosine phosphorylation of Src at Tyr416 in the
membrane fraction of H-2Kd-Ecad-II-4 cells. NS, nonsignificant.
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in FAK expression and activity was associated with changes
in Src kinase. Quantitative real-time reverse transcriptase-
PCR did not show an increase in Src mRNA level (Figure 1b),
and immunoblotting showed similar expression of Src in both
cell lines (Figure 1c). As Src recruitment to focal adhesions is
associated with its phosphorylation at Tyr416 (Roskoski,
2005), cell fractionation was performed (Figure 1d). Although
Src was detected in all cell fractions, it was highest in the
membrane fraction of both cell lines and its phosphorylation
at Tyr416 was threefold higher in H-2Kd-Ecad-II-4 cells than
in II-4 cells (Figure 1d). Thus, E-cadherin suppression in
SCC tumor cells resulted in upregulation of FAK mRNA and
protein levels that contributed to increased FAK and Src
activities.
To determine whether elevated FAK and Src activities
increase the motility of H-2Kd-Ecad-II-4 cells, cell motility
was analyzed in scrape-wounded II-4- and H-2Kd-Ecad-II-4
cultures in the presence of the inhibitors Tyrphostin AG1007
or PP2 (Supplementary Figure S1 online). Although augmen-
ted cell motility was observed in DMSO-treated H-2Kd-
Ecad-II-4 cultures relative to DMSO-treated-II-4 cultures,
inhibitor-treated cultures showed inhibition of wound closure
(Supplementary Figure S1 online) that was reversible upon
inhibitor removal from the media. Although Tyrphostin
AG1007 and PP2 are not specific only for FAK and Src,
and can affect other kinases, inhibition of the augmented
motility of H-2Kd-Ecad-II-4 cells was linked, at least in part,
to decreased FAK and Src phosphorylation to levels similar to
those found in DMSO-treated II-4 cells (Supplementary
Figure S2 online).
Prevention of the elevated activity of FAK or Src blocks
augmented motility and invasiveness of H-2Kd-Ecad-II-4 tumor
cells in vitro, and reverses SCC tumor phenotype in vivo
To determine whether upregulation of FAK or Src activity
in response to decreased E-cadherin levels is necessary for
the invasive phenotype of H-2Kd-Ecad-II-4 cells, we used
lentivirus-mediated short hairpin RNA (shRNA) to decrease
FAK or Src levels in these cells by generating stable sh-FAK-
and sh-Src-H-2Kd-Ecad-II-4 cell lines. Immunoblotting
revealed that FAK expression in sh-FAK-H-2Kd-Ecad-II-4 cells
and Src expression in sh-Src-H-2Kd-Ecad-II-4 cells were
reduced approximately 70 and 50%, respectively, when
compared with their levels in sh-Scrambled-H-2Kd-Ecad-II-4
cells (Figure 2a). In contrast, the expression level of another
Src family member, Fyn, was similar in these cell lines,
demonstrating specific downregulation of Src kinase in sh-
Src-H-2Kd-Ecad-II-4 cells (Supplementary Figure S3 online).
Next, scrape-wounding assay was performed to compare the
effect of FAK and Src shRNA-mediated depletion with the
pharmacological inhibition described earlier. In comparison
with the wound closure seen in sh-Scrambled-H-2Kd-Ecad-II-
4 cultures (Figure 2c), cell motility was inhibited in sh-FAK-
or sh-Src-H-2Kd-Ecad-II-4 cultures (Figure 2e and g, respec-
tively) and was similar to that seen in sh-Scrambled-II-4
cultures (Figure 2i). Although sh-Scrambled-H-2Kd-Ecad-II-4
cultures showed an average of 85% of wound closure at
24 hours, wound closure was significantly reduced to 58 and
40% in sh-FAK- or sh-Src-H-2Kd-Ecad-II-4 cultures, respec-
tively (Figure 2j). These findings show that the increase
in FAK and Src activities present in H-2Kd-Ecad-II-4 cells are
necessary for their augmented motility.
To test the concepts revealed using monolayer cultures in
a more physiologically relevant setting, an engineered human
skin tissue model was used. This 3D tissue model closely
mimics the features of the premalignant stages of SCC in
human stratified squamous epithelium (Alt-Holland et al.,
2005; Margulis et al., 2005). Tissues generated with sh-
Scrambled-H-2Kd-Ecad-II-4 cells showed separation between
epithelial cells (Figure 3a, arrows) and tumor cells that
invaded into the underlying matrix (Figure 3a, arrowheads).
In contrast, tissues harboring sh-FAK- (Figure 3b) or sh-Src-H-
2Kd-Ecad-II-4 cells (Figure 3c) revealed a greater degree of
basal cell layer organization and a significant decrease in
tumor cell invasion into the matrix (Figure 3d). These results
suggested that, upon E-cadherin loss, increased FAK and
Src activities in H-2Kd-Ecad-II-4 cells, above the level seen
in II-4 cells, is necessary for their invasive behavior in
3D tissues.
To determine how preventing the increase in FAK and
Src activities induced by E-cadherin loss might alter tumor
progression in vivo, tissues harboring H-2Kd-Ecad-II-4 cells,
sh-Scrambled-, sh-FAK-, or sh-Src-H-2Kd-Ecad-II-4 cells were
transplanted to the dorsum of nude mice. After 4 weeks, grafts
harboring H-2Kd-Ecad-II-4 cells (Figure 3e) or sh-Scrambled-
H-2Kd-Ecad-II-4 cells (Figure 3f) demonstrated large erythe-
matous tumors with raised irregular borders and central areas
of ulceration. In contrast, grafts harboring sh-FAK-H-2Kd-
Ecad-II-4 cells (Figure 3g) slowly enlarged, whereas sh-Src-H-
2Kd-Ecad-II-4 tumors remained as small exophytic nodular
tumors (Figure 3h). Tumor volume measurements showed
that H-2Kd-Ecad-II-4 or sh-Scrambled-H-2Kd-Ecad-II-4 tu-
mors had an approximately fourfold increase in their volume
when compared with sh-FAK- or sh-Src-H-2Kd-Ecad-II-4
tumors (Figure 3i). Tumor growth curves showed accelerated
development of H-2Kd-Ecad-II-4 and sh-Scrambled-H-2Kd-
Ecad-II-4 tumors compared with slower growth of sh-FAK-
and sh-Src-H-2Kd-Ecad-II-4 tumors (Figure 3j).
Next, tumor histology was analyzed by hematoxylin and
eosin staining, whereas tumor cell proliferation and the
degree of tumor differentiation were determined using anti-
Ki67 or anti-cytokeratin K1 antibodies, respectively. H-2Kd-
Ecad-II-4 (Figure 4a and e) or sh-Scrambled-H-2Kd-Ecad-II-4
(Figure 4b and f) tumors revealed sheets of pleiomorphic
poorly differentiated cells, areas of widened intercellular gaps
(Figure 4f, arrows), and cells that had separated from the
tumor edge and infiltrated into the surrounding stroma (Figure
4e, arrows). This aggressive pattern of invasion was asso-
ciated with the presence of Ki-67-positive tumor cells
throughout the tumor cell masses (Figure 4i and j), and the
absence of K1 (Figure 4m and n) indicated lack of cell
differentiation in these tumors. In contrast, sh-FAK-H-2Kd-
Ecad-II-4 tumors showed tumor cell sheets with well-defined
margins opposing the stroma (Figure 4c and g, arrowhead).
An increased degree of differentiation was evidenced by
keratin pearls (Figure 4g, arrow), a more limited distribution
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of Ki-67-positive cells to the periphery of the tumors
(Figure 4k), and scattered K1 staining in the inner area of
the tumors (Figure 4o). sh-Src-H-2Kd-Ecad-II-4 tumors were
affected to a greater degree as they revealed a switch to low-
grade tumors showing demarcated, well-differentiated tumor
islands with defined margins and central masses of keratin
(Figure 4d and h, arrows). Ki-67-positive tumor cells were
restricted to a basal position at the periphery of these
tumor islands (Figure 4l), associated with a strata-specific
K1 staining (Figure 4p, arrows). This tumor phenotype was
similar to that described previously for E-cadherin-competent
II-4 tumors (Margulis et al., 2005, 2006). These data show
that E-cadherin suppression in Ras-expressing keratinocytes
drives SCC development toward an aggressive tumor
phenotype, at least in part, through upregulation of FAK
and of Src that, in turn, promote tumorigenesis.
Prevention of the elevated activity of FAK or Src in H-2Kd-Ecad-
II-4 cells restores E-cadherin expression and its stability in
the plasma membrane
To reveal how prevention of the increased FAK and Src acti-
vities reverses the tumorigenic potential of H-2Kd-Ecad-II-4
cells, immunofluorescence analysis of E-cadherin in tissue
sections was performed. sh-Scrambled-H-2Kd-Ecad-II-4 tis-
sues showed a faint pattern of E-cadherin staining and cell
invasion into the underlying matrix (Figure 5a, arrow, inset).
Whereas K1 was absent (Figure 5d), Ki-67-positive cells
were seen throughout the epidermis (Figure 5g, arrowheads).
In contrast, tissues harboring sh-FAK-H-2Kd-Ecad-II-4 cells
showed increased E-cadherin staining at cell–cell borders
(Figure 5b). K1 expression was found in suprabasal layers of
the epidermis (Figure 5e), and proliferating Ki67-positive cells
were more restricted to the basal and immediate suprabasal
layers (Figure 5h), suggesting normalization of tissue pheno-
type. A more significant effect was seen in sh-Src-H-2Kd-
Ecad-II-4 tissues that demonstrated restoration of E-cadherin
localization at cell–cell borders (Figure 5c), increased K1
expression (Figure 5f), and restricted cell proliferation to the
basal layer of the epidermis (Figure 5i). These findings link
FAK and Src to the capacity of H-2Kd-Ecad-II-4 cells to
acquire invasive properties and to undergo a transition from
non-invasive to invasive tumor cell phenotype in 3D tissues.
They also show that downregulation of FAK or Src in invasive
epithelial tumor cells can block this process in 3D tissues by
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Figure 2. Decreased focal adhesion kinase (FAK) or Src expression in H-2Kd-Ecad-II-4 cells is associated with inhibition of tumor cell motility. (a) Western blot
(WB) analysis of lysates of sh-FAK- and sh-Src-H-2Kd-Ecad-II-4 cells showed a decrease in FAK or Src levels, respectively, when compared with their levels in sh-
Scrambled-H-2Kd-Ecad-II-4 cells. Scrape-wounded cultures of (b, c) sh-Scrambled-, (d, e) sh-FAK-, and (f, g) sh-Src-H-2Kd-Ecad-II-4 cells and of (h, i)
sh-Scrambled-II-4 cells were imaged at 0 and 24hours following injury. Lines indicate the wound gaps. (j) The mean±SD values of wound closure for each
cell line are indicated and show the average change in the gaps at 24 hours relative to time 0. The P-values indicate significant changes in wound closure
of sh-Scrambled-II-4, sh-FAK-, and sh-Src-H-2Kd-Ecad-II-4 cells in comparison with sh-Scrambled-H-2Kd-Ecad-II-4 cells.
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restoring a normalized tissue phenotype. These results
indicate that the decrease in E-cadherin expression associated
with the increase in FAK and Src activities has a critical
mechanistic role in directing the fate of H-2Kd-Ecad-II-4 cells
and tumor progression in this tissue model system. To further
investigate the effect of FAK and Src depletion on E-cadherin
in sh-FAK- or sh-Src-H-2Kd-Ecad-II-4 cells, the protein
and mRNA levels of E-cadherin in these cells were analy-
zed. E-cadherin expression was markedly decreased in
sh-Scrambled-H-2Kd-Ecad-II-4 cells compared with sh-
Scrambled-II-4 cells (Figure 5j). However, shRNA targeting
of FAK or of Src in H-2Kd-Ecad-II-4 cells resulted
in restoration of E-cadherin expression to the level seen in
sh-Scrambled-II-4 cells (Figure 5j), whereas no significant
changes in E-cadherin mRNA levels were observed
(Figure 5k).
Upon its removal from the cell membrane, E-cadherin
is either targeted to degradation or recycled back to the cell
membrane (Jeanes et al., 2008). To elucidate the possible
mechanism underlying the restoration of E-cadherin expres-
sion in sh-FAK- or sh-Src-H-2Kd-Ecad-II-4 cells, E-cadherin
turnover was assayed by treating cultures with 10 mM
Cycloheximide in order to block de novo protein synthesis
and to test whether FAK and Src depletion affected
E-cadherin stabilization at the plasma membrane. Immuno-
blotting revealed that, compared with Cycloheximide-treated
sh-Scrambled-II-4 cells, Cycloheximide-treated sh-
Scrambled-H-2Kd-Ecad-II-4 cells showed an accelerated
degradation of E-cadherin over 24 hours (Figure 5l). In
contrast, E-cadherin was considerably more stable in
Cycloheximide-treated sh-FAK- or sh-Src-H-2Kd-Ecad-II-4
cells, and under these conditions its levels were higher than
those of sh-Scrambled-II-4 cells (Figure 5l). Figure 5m
illustrates the percentages of the remaining E-cadherin in
the Cycloheximide-treated cultures over 24 hours relatively to
the corresponding Cycloheximide-treated cultures at time 0.
At the 24-hour time point, when compared with the
remaining 71% of E-cadherin in sh-Scrambled-II-4 cells,
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E-cadherin level in sh-Scrambled-H-2Kd-Ecad-II-4 cells de-
creased to 41%, whereas its levels in sh-FAK- or sh-Src-H-
2Kd-Ecad-II-4 cells were 72 and 70%, respectively. Under
these conditions, the exogenous H-2Kd-Ecad fusion protein
decreased similarly in sh-Scrambled-, sh-FAK-, and sh-Src-H-
2Kd-Ecad-II-4 cell lines (Supplementary Figure S4 online).
These data indicate that downregulation of FAK and Src in
sh-FAK- and sh-Src-H-2Kd-Ecad-II-4 cells, respectively,
contribute at least in part to a decrease in E-cadherin
degradation and an increase in E-cadherin stability in these cells.
DISCUSSION
This study reveals that loss of the suppressor of invasiveness,
E-cadherin, drives the early stages of Ras-induced SCC
progression through increased activation of FAK and Src that,
in turn, further directs destabilization of E-cadherin at the
plasma membrane, thus enhancing its degradation. Elevated
FAK and Src activities magnify the effect of E-cadherin
suppression, promote tumor cell invasion in engineered
tissues, and result in progression to an aggressive carcinoma
in vivo. Preventing FAK or Src upregulation resulted in
increased E-cadherin expression by enhancing its stability in
cell–cell contacts that, at least in part, blocked the invasive-
ness of H-2Kd-Ecad-II-4 cells and directed them to a more
normalized cell fate in 3D tissues. In vivo, these tissues
showed reversion of an aggressive high-grade tumor pheno-
type to a low-grade, indolent tumor behavior. These data
suggest a critical new mechanistic role for E-cadherin
suppression in directing FAK and Src upregulation as an
important component of early SCC development.
We have previously shown that loss of E-cadherin-
mediated adhesion in H-2Kd-Ecad-II-4 cells was linked to
increased integrin-mediated adhesion (Zhang et al., 2006)
and enhanced cell motility (Alt-Holland et al., 2008). This
interdependence between loss of cell–cell and gain of
cell–matrix adhesions suggested a co-activation of regulatory
H-2Kd-Ecad
K1
sh-Scrambled-H-2Kd-Ecad sh-FAK-H-2Kd-Ecad sh-Src-H-2Kd-Ecad
Figure 4. E-cadherin-suppressed H-2Kd-Ecad-II-4 cells exhibit a switch from high-grade to low-grade tumors upon downregulation of focal adhesion kinase
(FAK) or Src. Images of (a–d and in higher magnification e–h) hematoxylin and eosin (H&E), (i–l) Ki67 immunohistochemistry, and (m–p) K1 immunofluorescence
staining of tumor sections. (a, e) H-2Kd-Ecad- and (b, f) sh-Scrambled-H-2Kd-Ecad-II-4 tumors showed (e, f, arrows) poorly differentiated, invasive cells
and (i, j) Ki67-positive tumor cells, whereas (m, n) K1 was undetected. (c, g) sh-FAK-H-2Kd-Ecad-II-4 tumors showed (g, arrow) tumor cell differentiation,
(o) disperse K1, and (k) Ki67-positive cells that were more limited to the tumor invasive edge. (d, h) Well-differentiated sh-Src-H-2Kd-Ecad-II-4 tumor
islands showed (h, arrows) keratin pearls, (p, arrows) stratum-specific K1, and (l) Ki67-positive tumor cells at the periphery of the tumor clusters. Bar¼100 mm.
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events that could orchestrate and augment H-2Kd-Ecad-II-4
tumorigenic potential. FAK and Src, which are linked to
cadherins and integrins (Mitra and Schlaepfer, 2006; Zhao
and Guan, 2009) and are involved in tumor cell adhesion,
migration, and invasion (Summy and Gallick, 2003; Schlaep-
fer et al., 2004; Siesser and Hanks, 2006), emerged as
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candidates to regulate the behavior of these cells. FAK or Src
upregulation has been correlated with advanced stages of
cancer progression (Jones et al., 2000; Ishizawar and Parsons,
2004). For example, elevated expression and activation of
FAK has been linked to the progression of breast, colon,
prostate, and oral cancers (Withers et al., 1996; Tremblay
et al., 1996; Oktay et al., 2003; Schneider et al., 2002), and
amplification of the FAK gene has been shown in invasive
SCC (Agochiya et al., 1999). Increased Src activation has
been associated with head and neck SCC and breast cancers
(Reissig et al., 2001; Mandal et al., 2008). In colon cancer,
increased Src expression has been found in preneoplastic
lesions and activating mutations are seen in metastatic foci
(Irby et al., 1999). In this study, the use of in vitro 3D tissues
and in vivo transplants that closely mimic the features of early
stages of SCC in the human skin enabled us to analyze the
fate of E-cadherin-suppressed tumor cells in which FAK or Src
were either upregulated or suppressed. Here, we report that
E-cadherin suppression in the incipient stages of SCC drives
the upregulation of FAK mRNA and protein levels and of FAK
and Src activities above the level seen in E-cadherin-
competent II-4 cells. This increase is necessary for the
invasiveness of H-2Kd-Ecad-II-4 cells in 3D tissues, and
consequently for the progression of premalignant tissues to
aggressive carcinomas in vivo. A modest decrease in FAK or
Src was sufficient to inhibit the invasiveness of these cells by
restoration of E-cadherin at cell–cell borders and normal-
ization of tissue phenotype. This, in turn, resulted in reversion
of the aggressive tumor phenotype and inhibition of tumor
growth in vivo. These data demonstrate the critical regulatory
role of elevated FAK and Src activity in exacerbating the
tumor-promoting effect of decreased E-cadherin expression
during the early stages of SCC development.
How does increased activity of FAK and Src affect the
motility of early-stage E-cadherin-suppressed SCC tumor
cells? H-2Kd-Ecad-II-4 cells showed increased phosphoryla-
tion of the autophosphorylation site of FAK (Tyr397), the
activation domain of FAK (Tyr576/577), and FAK C-terminus
domain (Tyr925). FAK phosphorylation at Tyr925 has been
linked to focal adhesion turnover, cell spreading, and motility
(Katz et al., 2003). Thus, E-cadherin suppression in concert
with increased FAK activity and FAK phosphorylation on
Tyr925 can facilitate, at least in part, the augmented motility
of H-2Kd-Ecad-II-4 cells. In fibroblasts, depletion of the b1
integrin (Raghavan et al., 2003) or of FAK (Ilic et al., 1995)
resulted in increased numbers of focal contacts and inhibition
of cell motility, whereas stable reconstitution of FAK in
FAK-null fibroblasts promoted focal adhesion turnover and
enhanced cell motility (Sieg et al., 1999). In carcinoma cells,
increased FAK expression was correlated with enhanced cell
motility (Hauck et al., 2001), whereas depletion of FAK in
keratinocytes inhibited tumor formation (McLean et al.,
2004). Our study has extended these findings to show that
E-cadherin loss in H-2Kd-Ecad-II-4 cells led to increased FAK
and Src activity that consequently resulted in Src-mediated
hyperphosphorylation of FAK, leading to enhanced motility
of these cells. In supporting this, exposure of H-2Kd-Ecad-II-4
cells to FAK or Src inhibitors blocked their augmented
motility and led to decreased phosphorylation of FAK and Src
to a similar level seen in II-4 cells. Nevertheless, these
findings do not exclude the possible activation and involve-
ment of other Src family kinases, such as Fyn, in the
augmented neoplastic phenotype of H-2Kd-Ecad-II-4 cells
(Yadav and Denning, 2011).
How can upregulation of Src and FAK exacerbate
E-cadherin loss during the early stages of SCC? It has been
shown that overexpression of active Src in the colorectal
cancer cell line, KM12C, resulted in disruption of E-cadherin-
mediated adhesion that was dependent on Src-mediated FAK
phosphorylation (Avizienyte et al., 2002). Our study expands
these observations by showing that suppression of E-cadherin
function can also promote elevated Src activity and lead
to similar consequences of Src overexpression. Active Src
has also been shown to induce tyrosine phosphorylation of
cadherin–catenin complexes or regulators of adherens junc-
tions, resulting in E-cadherin endocytosis and disruption of
cadherin-mediated cell–cell adhesions, thus further enhan-
cing tumor cell motility (Fujita et al., 2002; Irby and Yeatman,
2002; Frame, 2004; Jeanes et al., 2008). However, an
alternative possibility to increased E-cadherin endocytosis
in H-2Kd-Ecad-II-4 is that degradation and turnover of
E-cadherin can also occur via MMP9-mediated E-cadherin
ectodomain shedding from the plasma membrane that can be
promoted by FAK or Src as seen in ovarian carcinoma cell
lines (Cowden Dahl et al., 2008; Symowicz et al., 2008). Our
findings suggest that as a result of E-cadherin suppression,
elevated Src activity can advance the early stages of SCC by
hyperphosphorylation of FAK and by further deregulating E-
cadherin-mediated adhesions. The fact that Src suppression
limits its accessibility to phosphorylate FAK and to further
decrease E-cadherin stability in the plasma membrane can
explain, at least in part, why sh-Src-H-2Kd-Ecad-II-4 tissues
showed a more profound degree of normalization in vitro and
a shift to a low-grade behavior in vivo compared with
sh-FAK-H-2Kd-Ecad-II-4 tissues. The findings that E-cadherin
suppression led to simultaneous activation of FAK and Src in
H-2Kd-Ecad-II-4 cells suggest that the interaction between
both kinases can amplify the tumorigenic potential of
Figure 5. Decreased focal adhesion kinase (FAK) or Src in H-2Kd-Ecad-II-4 cells is associated with upregulation and stabilization of E-cadherin protein leading
to normalization of tissue phenotype. Immunofluorescence staining of sh-Scrambled-H-2Kd-Ecad-II-4 tissue sections showed (a, arrow, inset) inconsistent
E-cadherin staining and cell invasion, and although (d) K1 was not detected, (g, arrowheads) Ki-67-positive cells appeared throughout the epidermis. sh-FAK-H-
2Kd-Ecad-II-4 tissues showed intense (b) E-cadherin staining, (e) K1 expression, and (h) Ki67-positive cells at the basal and immediate suprabasal layers.
sh-Src-H-2Kd-Ecad-II-4 tissues revealed (c) intense E-cadherin staining, (f) elevated K1, and (i) Ki67-positive cells at the basal layer. Bar¼ 100mm. (j) Although
an increase in E-cadherin protein was detected in sh-FAK- or sh-Src-H-2Kd-Ecad-II-4 cells, (k) E-cadherin mRNA level was not significantly changed.
(i) Representative western blot (WB) of E-cadherin in Cycloheximide-treated cultures, and (m) the mean±SD of the remaining E-cadherin in these cultures
in five independent experiments.
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E-cadherin-suppressed tumor cells. They also imply that
these kinases may exert complementary roles in regulating
tumor cell invasiveness during the early stages of SCC
development and the course of progression of this disease.
Collectively, our findings demonstrate an important new
role for E-cadherin in the early stages of SCC development.
Abrogation of E-cadherin-mediated adhesion in Ras-expres-
sing early-stage human epithelial tumor cells induces
elevated expression and/or activation of FAK and Src that
work in concert to promote aggressive tumor cell behavior
during incipient SCC development. Preventing the increase in
FAK and of Src activities profoundly altered tumor outcome
in vivo. As FAK and Src evolved as therapeutic targets for
cancer invasion and metastasis (McLean et al., 2005; Brunton
and Frame, 2008; Rucci et al., 2008), our findings suggest
that the premalignant stages of SCC development may be
inhibited by targeting these kinases in human epithelial cells
with neoplastic potential. Moreover, by further understanding
the events occurring in the progression of precancer to
malignancy in clinically relevant, in vivo-like human tissues,
new therapeutic approaches designed to block these events
may be formulated to impair early cancer invasion, thus
preventing SCC development or reoccurrence.
MATERIALS AND METHODS
Cells
Human foreskin fibroblasts were derived from newborn foreskins and
grown in DMEM with 10% fetal bovine serum (FBS, HyClone, Thermo
Scientific, Rockford, IL). HaCaT-II-4 keratinocytes (Boukamp et al.,
1990) were grown in DMEM (Invitrogen, Carlsbad, CA) with 5% fetal
bovine serum. H-2Kd-Ecad-II-4 cells were generated by retroviral
infection of HaCaT-II-4 cells as described (Margulis et al., 2005). II-4
and H-2Kd-Ecad-II-4 cells were infected with sh-Scrambled-, sh-FAK-, or
sh-Src-lentiviruses at a multiplicity of infection between 0.5 and 1.
Stable cell lines were selected with Blasticidin (7mg/ml; Invitrogen).
Cells were grown at 37 1C in 7.5% CO2. FAK or Src depletion was
confirmed by western blot analysis at the end of the selection process,
during cell passages, and before the fabrication of 3D tissues.
Construction of sh-FAK and sh-Src-mediated lentiviruses
Previously published small interfering RNA sequences to knock down
FAK (McLean et al., 2004; Tilghman et al., 2005) or Src (Trevino et al.,
2006; Wu et al., 2008) were designed into oligonucleotides (IDT, San
Diego, CA) with a loop sequence of tcaagaga. These oligonucleotides
were ligated into hairpin vectors using the BLOCK-iT Vector Kit
(Invitrogen) and recombined into pLenti6-DEST (Invitrogen). Lenti-
viruses expressing shRNA against FAK, Src, or a scrambled sequence
were titered using an end point dilution assay.
3D cell culture
Tissues harboring H-2Kd-Ecad-II-4 cells or sh-Scrambled-, sh-FAK, or
sh-Src-H-2Kd-Ecad-II-4 cells were generated as previously
described (Margulis et al., 2005). Briefly, 6 105 tumor cells were
seeded onto human foreskin fibroblast-populated type I collagen
gels, in deep-well polycarbonate tissue culture inserts (Organogen-
esis, Canton, MA). Cultures were maintained submerged for 3 days
in low-calcium epidermal growth medium and for 2 days in
normal-calcium epidermal growth medium before they were raised
to an air–liquid interface for 7 days.
In vivo tissue transplantation
All animal experiments were conducted according to a protocol
approved by the Tufts University Institutional Animal Care and Use
Committee. Briefly, a 1.3 cm skin section from the dorsum surface of
6-week-old male Swiss nude mice (N:NIHS-nuf DF; Taconic Farms,
Germantown, NY) was removed from groups of nX3 per cell line,
and tissues were transplanted at the excision site. Following bandage
removal, tumor volume was estimated using the formula volu-
me¼ lengthwidth height. Mice were killed 4 weeks after
grafting, and tumors were excised and processed as described
(Margulis et al., 2006).
Quantification of cell invasion
For each fabricated tissue, events of tumor cell invasion into the
matrix were counted and averaged from 4100 microscope fields
in 420 sections from multiple experiments. Averages represent X3
independent experiments±SD. The P-values were calculated using
the Mann–Whitney test.
E-cadherin protein turnover
Cell cultures were treated with either 10 mM DMSO (vehicle) or
Cycloheximide (Sigma, St Louis, MO) for 0, 4, 8, 16, and 24 hours,
and cell lysates were subjected to western blot analysis. Immuno-
blots of three independent experiments were quantified by
densitometry, using Image J software (Java-based image processing
program, NIH; http://rsb.info.nih.gov/ij/). The percentage of the
remaining E-cadherin was measured relative to treatment with
DMSO and reported as a value relative to time 0.
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